**A need of COVID19 vaccination for children aged <12 years:
Comparative evidence from the clinical characteristics in
patients during a recent Delta surge (B.1.617.2)**

Hongru Li¹ Haibin Lin^{2*} Xiaoping Chen^{3*} Hang Li² Hong Li⁴ Sheng Lin¹
Liping Huang¹ Gongping Chen⁵ Guilin Zheng⁶ Shibiao Wang⁷ Xiaowei
Hu⁸ Handong Huang⁹ Haijian Tu¹⁰ Xiaoqin Li¹ Yuejiao Ji³ Wen Zhong¹
Qing li¹ Jiabin Fang¹ Qunying Lin^{# 6} Rongguo Yu^{11#} Baosong Xie

1 Department of Respiratory and Critical Care Medicine, Fujian
Provincial Hospital, Fujian Shengli Medical College, Fujian Medical
University , Fuzhou , 35001 , China

2 Affiliated Hospital of Fujian Putian University , Putian, Fujian ,
351100, China

3 College of Mathematics and Statistics, Fujian Normal University ,
Fuzhou , 350117 , China

4 Fujian Provincial Hospital , Fuzhou , 35001 , China

5 Department of Respiratory and Critical Care Medicine, the First
Affiliated Hospital of Fujian Medical University, Fuzhou , 35001 , China

6 Department of Respiratory and Critical Care Medicine, Affiliated
Hospital of Putian University, Putian, Fujian , 351100, China

20 7 Fujian Maternal and Child Health Hospital ,Fuzhou ,35001 ,China

21 8 Fujian Hospital of Shanghai Children's Medical Center , Fuzhou ,

22 35001 , China

23 9 Department of Internal Critical Medicine, Affiliated Hospital of

24 Putian University, Putian, 351100, China

25 10 Department of Laboratory Medicine, Affiliated Hospital of Putian

26 University, Putian, Fujian Province , 351100, China

27 11Department of Surgical Critical Medicine, Fujian Provincial

28 Hospital, Fuzhou , 35001 , China

29 * Co-first authors

30 # Co-corresponding authors

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

Abstract: Objective: To evaluate the necessity of Covid-19 vaccination in children aged < 12 y by comparing the clinical characteristics in unvaccinated children aged < 12 y with vaccinated patients aged ≥ 12 y during the Delta surge (B.1.617.2) in Putian, Fujian, China. **Methods:** A total of 226 patients with SARS-Cov-2 Delta variant (B.1.167.2; confirmed by Realtime PCR positive and sequencing) were enrolled from Sep 10th to Oct 20th, 2021, including 77 unvaccinated children (aged < 12y) and 149 people aged ≥ 12 y, mostly vaccinated. The transmission route was explored and the clinical data of two groups were compared ; the effect factors for the time of the nucleic acid negativization (NAN) were examined by R statistical analysis. **Results:** The Delta surge in Putian spread from children in schools to factories, mostly through family contact. Compared with those aged ≥ 12 y, patients aged < 12y accounted for 34.07% of the total and showed milder fever, less cough and fatigue; they reported higher peripheral blood lymphocyte counts $[1.84(1.32,2.71) \times 10^9/L$ vs. $1.31(0.94,1.85) \times 10^9/L$; $p < 0.05$), higher normal CRP rate (92.21% vs. 57.72%), lower IL-6 levels $[5.28(3.31,8.13)$ vs. $9.10(4.37,15.14)$; $p < 0.05$]. Upon admission, their COVID19 antibodies (IgM and IgG) and IgG in convalescence were lower $[0.13(0.00,0.09)$ vs. $0.12(0.03,0.41)$, $p < 0.05$; $0.02(0.00,0.14)$ vs. $1.94(0.54,6.40)$, $p < 0.05$; $5.46(2.41,9.26)$ vs. $73.63 (54.63,86.55)$, $p < 0.05$, respectively], but longer NAN time (18

69 days vs. 16 days, $p=0.13$). **Conclusion:** Children aged $< 12y$ may be
70 critical hidden spreaders, which indicates an urgent need of vaccination
71 for this particular population.

72 **Keywords:** COVID 19; children; delta variants; clinical features;
73 vaccination

74

75 **Introduction**

76 Since its outbreak in early 2020, Covid-19 has caused a global pandemic,
77 with a cumulative total of over 235,634,315 infections and a toll of tens
78 of thousands of deaths (4,973,007 in total as of October 27, 2021). Amid
79 the development of the Covid-19 pandemic, several mutants of the virus
80 have been discovered, including Alpha (the B.1.1.7 in the United
81 Kingdom), Beta (the B.1.351 in South Africa), Gamma, Lamda, Delta etc.,
82 among which the Delta variant (B.1.617.2) was first identified in
83 Maharashtra in late 2020 [1] and spread to India and then to at least more
84 than 180 countries or regions, making it the most aggressive widespread
85 variant around the world. The first locally-transmitted case of Delta
86 variant in China was reported in Guangzhou on May 21, 2021, which was
87 introduced by imported overseas cases and resulted in a total of 167
88 localized outbreaks. So far, four more surges have been reported
89 successively in Yunnan Ruili Airport, Nanjing Lukou Airport, Zhengzhou
90 and Putian. Studies have shown that compared with the wild strain, the

91 Delta variant shows characteristics of a shorter incubation period (4.7 vs.
 92 6.3 days), faster transmission, higher viral load (10^6 vs. 10^4 copies)
 93 and significantly longer time for nucleic acid negativization (NAN), and
 94 deteriorates 2.98 times faster and 1.45 times more likely into a critical
 95 status for the elderly patient population aged 60 years and older [2]. The
 96 global launch of the vaccination against Covid-19 has been effective for
 97 the delta variant, with Pfizer bioNTech reducing the symptomatic
 98 population from 94% to 64% and Oxford AstraZeneca from 73% to 60% [3]
 99 and Moderna vaccine (mRNA 1273) preventing 81% of hospitalizations
 100 and 76% of infections and Pfizer bioNTech (BNT162B2) vaccine
 101 reducing 75% of hospitalizations and 42% of infections [4]. Several
 102 studies have also shown that vaccination provides 90% protection for
 103 frontline workers [5]. The CDC in the United States cautions that people
 104 who have not been vaccinated will face an infection risk of 11 times
 105 higher [6]. All these findings suggest that the Covid-19 nucleic acid
 106 vaccination can provide effective protection from Delta variant infection
 107 and prevent it from developing into severe diseases. On the other hand,
 108 the L452R and P681R mutants of Delta (B.1.617.2) enhance its binding
 109 to the ACE2 receptor of human alveolar epithelial cells, inducing faster
 110 transmission, and trigger immune escape, resulting in compromised
 111 vaccination and impaired immunity [7-11]. Studies showed that after
 112 vaccination, the viral load in patients infected with the Delta variant was

113 equivalent to that of unvaccinated patients [12]. Moreover, the protection
114 against Delta variant is weaker than against other mutant strains, which
115 may result in breakthrough cases [13], which has posed new challenges to
116 the global efforts in containing the Covid-19 pandemic.

117 At present, vaccination programs for adolescents (≥ 12 years of age) have
118 been approved and implemented in countries such as China, the United
119 States, and the United Kingdom, but no mass vaccination has been
120 conducted globally for children and adolescents under the age of 12 years
121 due to remaining controversies over the risk-benefit issues of vaccination
122 in children and adolescents [14, 15]. Studies have shown that children
123 generally have favorable prognosis and only experience mild symptoms,
124 ranging from symptoms of acute upper respiratory tract infection, mild
125 fever, to digestive symptoms such as nausea, vomiting, abdominal pain,
126 and diarrhea, which may account for the hesitation of a vaccination need
127 for this particular population [16]. On the other hand, some scholars
128 believe that the negligence of these infected children often turns them
129 into hidden spreaders of the virus and aggravates the epidemic [17]. A
130 study once proposed a mathematical model of SEIR disease transmission
131 with the United Kingdom as an example and projected that if adolescents
132 and children were included in the vaccination program, the overall
133 COVID-19 mortality rate would be reduced by 57% and the number of
134 long-term COVID-19 infection cases would be reduced by 75% [18]. The

findings from this study suggest that vaccination in children may play an important role in reducing the overall morbidity and mortality of COVID-19. According to the current vaccination policy in China, the children under 12 years of age in this Putian surge (accounting for over 30% of the total) were not yet vaccinated against Covid-19 while most patients over 12 years of age were vaccinated, so a comparative analysis of the epidemic and its characteristics in this population will help determine the necessity of vaccination in children under 12 years of age.

Study design and participants

The study enrolled a total of 226 individuals with positive SARS-CoV-2 Delta VOC (confirmed by SARS-Cov-2 PCR), who were admitted to the designated hospital (The Affiliated Hospital of Putian University) from September 10 to October 20, 2021. Relevant information was collected regarding the patients' epidemiological details, clinical data, laboratory results, kinetics of viral load, and information of last negative nucleic acid test. According to the current vaccination policy of China, the individuals were divided into two groups: Group 1 (aged<12y), who had not been vaccinated, and Group 2 (aged ≥12y), most of whom had been vaccinated with Chinese inactivated vaccine from Sinopharm or Sinovac company.

Data collection

Standardized data collection forms were employed to collect, from

157 electronic medical records, the clinical and laboratory data, including
 158 clinical manifestations, laboratory results, treatment and prognosis. In
 159 terms of laboratory data, the cycle threshold (CT) value was measured by
 160 SARS-Cov-2 real-time PCR and the serological results included blood
 161 test, biochemical analysis, CRP, IL-6, SARS-CoV-2 IgG antibody titer,
 162 blood coagulation function, and microbe testing. The above serological
 163 tests were performed 24 hours after admission and antibody in
 164 convalescence was tested within 10 to 20 days after admission. The first
 165 day of onset was designated as the day of COVID-19 diagnosis for
 166 asymptomatic patients and the day of COVID-19 symptoms or the day of
 167 COVID-19 diagnosis (whichever was earlier) for symptomatic patients.
 168 On the 10th day of the disease course, nasopharyngeal swabs were
 169 administered every day until the negative nucleic acid testing was
 170 successively reported twice with an interval of over 24 hours. The time
 171 for NAN was defined as the duration from the first day of positive nucleic
 172 acid report to the time of the second negative nasopharyngeal swab
 173 testing of the two successive negative nucleic acid tests [19].

174 **Viral RNA sequencing**

175 Fujian Provincial CDC performed the whole genome second-generation
 176 sequencing of the SARS-Cov-2 specimens by positive fluorescence
 177 real-time PCR. The epidemic strain was confirmed to be the Delta variant
 178 (B.1.617.2), with which all patients were infected.

179 **Clinical management**

180 All enrolled COVID-19 patients were admitted to the hospital,
 181 quarantined, and monitored for their vital signs, body temperature and
 182 respiration. Patients whose SpO₂ was lower than 93% were treated with
 183 oxygen therapy. Most patients were treated with Chinese traditional
 184 medicine. Some patients with fever or severe illness received the
 185 treatment of BR1196/198 neutralizing antibody after informed consent.
 186 According to the national guidelines, glucocorticoids were only suitable
 187 for specific people, and antibiotics were used for patients with bacterial
 188 infections. In terms of disease severity, all patients were classified as
 189 asymptomatic, mild (no pneumonia by chest radiography), moderate
 190 (pneumonia by chest CT), severe (SpO₂<93%; oxygen therapy required),
 191 or critical (RICU admission or mechanical ventilation required). Patients
 192 were discharged when the discharging standards were met [19]. The
 193 collection of clinical data was reviewed at discharge.

194 **Statistical Analysis**

195 All data were analyzed with the SPSS 23 software. The data of
 196 continuous parameters were expressed as mean (variance), or median
 197 (interquartile range, IQR), and assessed by T-test for normal variables and
 198 Wilcoxon rank sum test for non-normal variables. Categorical variables
 199 were presented as frequency (percentage) and analyzed by Chi Square
 200 test and Fisher's precision probability test. The NAN-related factors were

201 estimated by the least-absolute method with R data analysis software.
202 Two-tailed p value of less than 0.05 was considered statistically
203 significant.

204 **Ethics approval**

205 All patients signed informed consent and the ethics approval was granted
206 by the Ethics Committee of the Affiliated Hospital of Putian University
207 (No.202152)

208 **Results**

209 **Baseline information of the patients**

210 A total of 226 infections were enrolled, of which 77 cases were under the
211 age of 12 years (34.07%), with 44 males (57.14%) and a median age of
212 9[6,9], and 149 cases were aged ≥ 12 years (65.93%), with 50 males
213 (33.56%) and a median age of 39[32,50]. The children aged $<12y$ were
214 unvaccinated and had no underlying conditions, while 94.63% (141/149)
215 of patients aged ≥ 12 years were vaccinated, of whom 9 (6.04%) received
216 one dose of vaccine and 132 (88.59%) received two doses of vaccine and
217 18 (12.08%) reported coexisting conditions (11 diabetes, 6 hypertension,
218 and 1 chronic kidney disease) (Table 1). On admission, the detected
219 RT-PCR cycle threshold values (CT value) of children aged $<12y$ were
220 almost the same as that of patients aged $\geq 12y$ [ORF1lab value:
221 21.28(17.74, 26.15) vs. 23.21(17.09, 27.51), $p=0.38$; N value:
222 20.68(15.93, 25.33) vs. 22.50(15.59, 26.79), $p=0.46$] (Table 2).

223 **Transmission route of SARS-CoV-2 Delta (B.1.617.2) in Putian**

224 In this local surge in Putian, Fujian, the first index case was a
225 middle-aged male, who was infected during quarantine after entry into
226 China and transmitted the SARS-CoV-2 Delta (B.1.617.2) to his two
227 children (G1). The activities of the children in the school spread the virus
228 to their classmates (G2), which further extended the transmission to the
229 factories(G4) through family contact(G3). All of these cases were
230 epidemiologically or genetically traced back to the first case (The specific
231 transmission route is shown in Fig1).

232 **Comparison of clinical characteristics in patients aged <12y and** 233 **those aged ≥12 y**

234 Compared with patients aged ≥12y, 75.32% (58/77) of children aged
235 <12y developed milder fever ($p<0.05$), minor symptoms such as cough
236 (18.18% vs. 44.30%, $p<0.05$), expectoration (7.79% vs. 24.16%, $p<0.05$)
237 and fatigue (16.88% vs. 34.23%, $p<0.05$). But no significant difference
238 was found in the day of fever onset after diagnosis [1(1,3) vs. 2(1,4)] and
239 duration of fever [1 day(0,2.5) vs. 1day(0,3.5), $p>0.05$] (Table 2).

240 Compared with those aged ≥12y, the younger group reported higher
241 white blood cell count [$5.89(1.90)\times 10^9/L$ vs. $6.45(2.04)\times 10^9/L$, $p=0.05$]
242 and lymphocyte count [$1.84(1.32,2.71)\times 10^9/L$ vs.
243 $1.31(0.94,1.85)\times 10^9/L$, $p<0.05$], higher normal CRP rate (92.21% vs.
244 57.72%) ($p<0.05$), lower IL-6 levels [$5.28(3.31,8.13)$ vs.

245 9.10(4.37,15.14), $p < 0.05$]; they also showed lower levels of COVID-19
246 antibody IgM and IgG on admission and IgG in convalescence
247 [0.13(0.00,0.09) vs. 0.12(0.03,0.41), $p < 0.05$; 0.02(0.00,0.14) vs.
248 1.94(0.54,6.40), $p < 0.05$; 5.46(2.41,9.26) vs. 73.63(54.63,86.55), $p <$
249 0.05, respectively], but higher antibody IgM in convalescence
250 [1.05(0.51,2.31) vs. 0.51(0.20,1.69), $p=0.016$] ((Table 2, Fig2).
251 Compared with patients aged ≥ 12 y, the younger group had milder illness
252 ($p < 0.05$), with a higher asymptomatic rate (6.49% vs. 0%), more mild
253 cases (44.16% vs. 32.89%), and fewer moderate and severe and critical
254 cases (49.35% vs. 63.09 %; 0% vs. 4.02%, respectively); they also had a
255 lower frequency of pneumonia (53.25% vs. 63.09%, $p=0.05$) and
256 respiratory failure (0% vs. 4.03%) but longer NAN median [18(13,23.5)
257 vs. 16(12,21), $p=0.13$]. In the infected patients aged ≥ 12 y, 5 patients was
258 admitted to ICU, with a median stay length of 9 days [7, 21], 2 (1.34%)
259 receiving endotracheal intubation; 42 (28.19%) received BR1196/198
260 neutralizing antibody therapy; 5 (3.36%) were given convalescent plasma;
261 and 2 people (1.34%) received hormones treatment. However, no such
262 treatments were administered to the children aged < 12 y (Table 2).

263 **Analysis of factors related to NAN**

264 The data were modeled by R data analysis software. The results showed
265 that the younger group reported a much longer NAN time when
266 compared with patients aged ≥ 12 y, which was negatively correlated with

the IgG level on admission, the days of fever onset after diagnosis, and the nucleic acid CT value (ORF1lab) on admission, but positively with the occurrence of pneumonia, the degree of fever, and the severity of the disease (Table 3).

Discussion

SARS-CoV-2 B.1.617.2 (Delta variant) first emerged in October 2020 and has been prevalent in the world (<https://www.gisaid.org/hcov19-variants/>). The transmission rate of the SARS-COV-2 Delta variant increases by 97% when compared with that of the wild-type strain [20]. Patients infected with Delta variant are twice likely to be hospitalized when compared with those with Alpha variant [21]. In the Guangdong Delta variant surge (May 2021), the viral load in patients was about 1,000 times higher than that of those infected with the original 2019 coronavirus strain [2]. The viral load and transmission speed in the Putian Delta variant surge (Sept. 10th, 2021) were similar to those in Guangzhou. But, in the Putan surge, children were the first and prominent spreaders, which is consistent with the findings of other studies. Previous studies show that school and family are critical transmission places for SARS-COV-2 [22, 23], in which the risk of household transmission was expected to be 60% higher for the Delta variant than for the Alpha variant [24]. In summary, children can be critical spreaders in the epidemic of Delta variant.

289 The Putian Delta variant surge revealed characteristics of younger
 290 individuals, milder symptoms and higher vaccination rate. Most of the
 291 patients aged $\geq 12y$ had been vaccinated with two doses of inactivated
 292 SARS-COV-2 vaccine while only 1/5 of the patients in Guangdong Delta
 293 surge (May 2021) were vaccinated [25]. Of note, the current study
 294 showed that for patients aged $\geq 12y$, the Delta variant-related diseases
 295 were much milder in Putian than in Guangzhou surge, with fewer than
 296 one-fifth severe cases [25], which is consistent with the results of
 297 previous studies [26-28].

298 In addition, the median NAN time was obviously shorter than that in
 299 Guangzhou (16 vs. 19 days) [25]. Further analyses showed that the
 300 COVID-19 antibody IgG in the vaccinated population (aged $\geq 12y$)
 301 increased much more rapidly and was higher than that of the
 302 unvaccinated minor group. Furthermore, a previous study documents that
 303 the nucleic acid CT value of the vaccinated group increased more rapidly
 304 than that of the unvaccinated group, indicating a much faster virus
 305 clearance by vaccination [7]. Taken together, these findings suggest that
 306 vaccination can provide sufficient protection from disease deterioration
 307 and accelerate the elimination of virus.

308 However, the mutation of SARS-COV-2 delta variants may cause
 309 immune escape and reduce the sensitivity to neutralizing antibodies,
 310 leading to the breakthrough infection of Delta variants even after

311 vaccination [13]. Therefore, delta variants may still be potent for quite a
312 long time in the future and unvaccinated children may be critical hidden
313 spreaders due to the absence of effective immunity barrier. In our cohort,
314 children aged <12 y were unvaccinated and accounted for more than 1/3
315 of the total patient population, much more than those in Guangzhou [25].
316 In accordance with previous studies, the symptoms of this group were
317 mild as a whole, with milder fever, fewer other symptoms, and no severe
318 cases, when they were compared with those who were over the age of 12
319 years and vaccinated [25, 29]. They had higher lymphocyte counts, as in
320 Vono M's study [30], which may be related to the innate immunity of this
321 population [31-33]. Lower levels of CRP and IL-6 may indicate a lower
322 overall inflammatory response and a good prognosis [34].
323 However, in contrast to the mild symptoms, the overall median NAN time
324 of children under the age of 12 years was longer than that of those aged
325 12y and over. Although studies show that virus inactivation time is much
326 shorter than the NAN time [35], the NAN time is still closely related to
327 the elimination of virus and its infectivity. Further analysis showed that
328 the population aged <12y and the COVID-19 IgG level on admission
329 were two of the most important factors for NAN time. We hypothesize
330 that as they are unvaccinated, the production of novel antibody is slower
331 in the population aged <12y, resulting in slow virus clearance. These
332 results suggest that if no due attention is paid to children with mild

333 symptoms, they may carry the virus for a longer time and become hidden
334 disseminators of Delta virus.

335 Previous studies have showed that a large number of RBD specific IgG
336 memory B cells can be induced after mild infection with COVID-19 virus
337 [36]. Children's B lymphocytes may be activated faster and can produce
338 much more effective antibodies [30]. The vaccination can produce more
339 memory B lymphocytes in the younger population, which may promote
340 antibody production and speed up virus clearance in the early stage of
341 SARS-CoV-2 infection, so as to reduce their risk as hidden
342 communicators. Therefore, despite the lingering medical disputes, we
343 believe that it is of great significance to promote vaccination in the
344 population aged <12y in order to combat the novel sars-cov-2 variant. It
345 is worth mentioning that, presently, the clinical trials with the mRNA
346 1273 and bnt162b2 vaccines of Pfizer company [37], and the inactivated
347 vaccines (coronavac) of Kexing and Sinopharm company have been
348 carried out in children and adolescents aged 3-17y, which reported a high
349 serum conversion rate of neutralizing antibody (96% ~ 100%) and
350 favorable overall safety [38, 39]. The Chinese government has recently
351 approved the emergency use of COVID-19 inactivated vaccine in the
352 population aged 3-17 [40]. However, as the immune system of children,
353 especially infants, is in the process of continuous development and
354 improvement and the relevant application data of covid-19 vaccine is

355 limited at present, more clinical trials should be conducted to clarify the
356 efficacy and risk. Accordingly, it is suggested that COVID-19 vaccination
357 for children should be promoted in an orderly manner and that the
358 effectiveness and adverse reactions of vaccination should be closely
359 monitored [40].

360 Some limitations still remain in this study: 1. Although the transmission
361 route of all cases was relatively clear and complete, data only came from
362 local patients of Putian, so no multi-center data are accessed. 2. Although
363 COVID-19 antibodies IgM and IgG had been detected, neutralizing
364 antibody (RBD) was not tested and immunofunctional studies were not
365 conducted. Further studies should be pursued to better evaluate the
366 immune function of children age <12 in order to unravel the underlying
367 mechanisms.

368

369 **Acknowledgements**

370 The research was funded by the following grants, including Fujian
371 Science and Technology Guidance Project: Research on the immune
372 response system of patients infected with variant strains of the new
373 coronavirus (2021Y0100), Fujian Natural Science Foundation
374 (2019J01178), Central Government Guiding Local Science and
375 Technology Development (2021L3018), Natural Science Foundation of
376 Fujian Province (2021J01658), High-level hospital foster grants from

377 Fujian Provincial Hospital, Fujian province, China (NO.2019HSJJ11).

378 We thank Professor Hongzhi Huang for proofreading and polishing the

379 manuscript.

380

381 Reference

- 382 1. Cherian S, Potdar V, Jadhav S, et al. Convergent evolution of SARS-CoV-2 spike mutations, L452R,
383 E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. 2021:
384 2021.2004.2022.440932.
- 385 2. Li, B. et al. Preprint at medRxiv <https://doi.org/10.1101/2021.07.07.21260122> (2021).
- 386 3. Baraniuk C. Covid-19: How effective are vaccines against the delta variant? *BMJ (Clinical research*
387 *ed)* 2021: 374: n1960.
- 388 4. Grannis SJ, Rowley EA, Ong TC, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against
389 COVID-19-Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations
390 Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance - Nine States, June-August
391 2021. *MMWR Morbidity and mortality weekly report* 2021: 70(37): 1291-1293.
- 392 5. Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 Vaccines in Preventing
393 SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant
394 Predominance - Eight U.S. Locations, December 2020-August 2021. *MMWR Morbidity and mortality*
395 *weekly report* 2021: 70(34): 1167-1169.
- 396 6. Dyer O. Covid-19: Unvaccinated face 11 times risk of death from delta variant, CDC data show.
397 *BMJ (Clinical research ed)* 2021: 374: n2282.
- 398 7. Chia PY, Xiang Ong SW, Chiew CJ, et al. Virological and serological kinetics of SARS-CoV-2 Delta
399 variant vaccine-breakthrough infections: a multi-center cohort study. 2021:
400 2021.2007.2028.21261295.
- 401 8. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2
402 lineage B.1.1.7 in England. *Science (New York, NY)* 2021: 372(6538).
- 403 9. Dyer O. Covid-19: Delta infections threaten herd immunity vaccine strategy. *BMJ (Clinical*
404 *research ed)* 2021: 374: n1933.
- 405 10. Pritchard E, Matthews PC, Stoesser N, et al. Impact of vaccination on new SARS-CoV-2 infections
406 in the United Kingdom. *Nature medicine* 2021: 27(8): 1370-1378.
- 407 11. Pung R, Mak TM, Kucharski AJ, et al. Serial intervals in SARS-CoV-2 B.1.617.2 variant cases. *Lancet*
408 *(London, England)* 2021: 398(10303): 837-838.
- 409 12. Griffin S. Covid-19: Fully vaccinated people can carry as much delta virus as unvaccinated people,
410 data indicate. *BMJ (Clinical research ed)* 2021: 374: n2074.
- 411 13. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and
412 immune evasion. *Nature* 2021.
- 413 14. GOV.UK. Press Release: JCVI Issues Advice on COVID-19 Vaccination of Children and Young People.
414 2021. Available online:
415 [https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-vaccination-of-children-and-yo](https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-vaccination-of-children-and-young-people)
416 [ung-people](https://www.gov.uk/government/news/jcvi-issues-advice-on-covid-19-vaccination-of-children-and-young-people) (accessed on 26 July 2021).
- 417 15. U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes
418 Pfizer-BioNTech COVID-19 Vaccine for Emergency Use in Adolescents in Another Important Action in
419 Fight Against Pandemic 2021. Available online:
420 [https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use)
421 [-pfizer-biontech-covid-19-vaccine-emergency-use](https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-pfizer-biontech-covid-19-vaccine-emergency-use) (accessed on 26 July 2021).
- 422 16. Schroeder AR, Wilson KM, Ralston SL. COVID-19 and Kawasaki Disease: Finding the Signal in the
423 Noise. *Hospital pediatrics* 2020: 10(10): e1-e3.

17. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. *The Journal of pediatrics* 2020; 227: 45-52.e45.
18. Shiri T, Evans M, Talarico CA, et al. Vaccinating Adolescents and Children Significantly Reduces COVID-19 Morbidity and Mortality across All Ages: A Population-Based Modeling Study Using the UK as an Example. *Vaccines* 2021; 9(10).
19. National Health Commission & State Administration of Traditional Chinese Medicine. Diagnosis and treatment protocol for novel coronavirus pneumonia (Trial Version 8). August 18, 2020. Available at: <http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml>.
20. Campbell F, Archer B, Laurenson-Schafer H, et al. Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021. *Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin* 2021; 26(24).
21. Twohig KA, Nyberg T, Zaidi A, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. *The Lancet Infectious diseases* 2021; S1473-3099(21)00475-8.
22. Lam-Hine T, McCurdy SA, Santora L, et al. Outbreak Associated with SARS-CoV-2 B.1.617.2 (Delta) Variant in an Elementary School - Marin County, California, May-June 2021. *MMWR Morbidity and mortality weekly report* 2021; 70(35): 1214-1219.
23. Madewell ZJ, Yang Y, Longini IM, et al. Factors Associated With Household Transmission of SARS-CoV-2: An Updated Systematic Review and Meta-analysis. *JAMA network open* 2021; 4(8): e2122240.
24. Mahase E. Delta variant: What is happening with transmission, hospital admissions, and restrictions? *BMJ (Clinical research ed)* 2021; 373: n1513.
25. Wang Y, Chen R, Hu F, et al. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. *EClinicalMedicine* 2021; 40: 101129.
26. Jara A, Undurraga EA, González C, et al. Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile. *The New England journal of medicine* 2021; 385(10): 875-884.
27. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *The New England journal of medicine* 2021; 385(7): 585-594.
28. Sheikh A, McMenamin J, Taylor B, et al. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. *Lancet (London, England)* 2021; 397(10293): 2461-2462.
29. Islam MA, Kundu S, Alam SS, et al. Prevalence and characteristics of fever in adult and paediatric patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis of 17515 patients. *PloS one* 2021; 16(4): e0249788.
30. Vono M, Huttner A, Lemeille S, et al. Robust innate responses to SARS-CoV-2 in children resolve faster than in adults without compromising adaptive immunity. *Cell reports* 2021; 37(1): 109773.
31. Viau M, Zouali M. B-lymphocytes, innate immunity, and autoimmunity. *Clinical immunology (Orlando, Fla)* 2005; 114(1): 17-26.
32. Bieberich F, Vazquez-Lombardi R, Yermanos A, et al. A Single-Cell Atlas of Lymphocyte Adaptive Immune Repertoires and Transcriptomes Reveals Age-Related Differences in Convalescent COVID-19 Patients. *Frontiers in immunology* 2021; 12: 701085.
33. Güneş H, Dinçer S, Acıpayam C, et al. What chances do children have against COVID-19? Is the answer hidden within the thymus? *European journal of pediatrics* 2021; 180(3): 983-986.

468 34. Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in
469 patients with COVID-19. *Journal of clinical virology : the official publication of the Pan American*
470 *Society for Clinical Virology* 2020; 127: 104370.

471 35. Kim MC, Cui C, Shin KR, et al. Duration of Culturable SARS-CoV-2 in Hospitalized Patients with
472 Covid-19. *The New England journal of medicine* 2021; 384(7): 671-673.

473 36. Rodda LB, Netland J, Shehata L, et al. Functional SARS-CoV-2-Specific Immune Memory Persists
474 after Mild COVID-19. *Cell* 2021; 184(1): 169-183.e117.

475 37. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *The*
476 *New England journal of medicine* 2021; NEJMoa2109522..

477 38. Han B, Song Y, Li C, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
478 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled,
479 phase 1/2 clinical trial. *The Lancet Infectious diseases* 2021; S1473-3099(21)00319-4..

480 39. Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated COVID-19 vaccine,
481 BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
482 *The Lancet Infectious diseases* 2021; S1473-3099(21)00462-X..

483 40. Zheng YJ, Wang XC, Feng LZ, et al. Expert consensus on COVID-19 vaccination in children. *World*
484 *journal of pediatrics : WJP* 2021; 17(5): 449-457.

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500 **Fig1 The transmission network of SARS-Cov-2 Delta (B.1.167.2) in Putian**

501 The transmission chain of the 226 infected patients was shown in the network. Each
502 transmission generation is shown in rhombus or circles with different colors. The
503 first-generation patients (rhombus with black solid line, G1) were in the middle. G1
504 was phylogenetically linked to an imported case (rhombus with red dotted line, G0).
505 Colored arrows indicate different transmission routes. The transmission includes
506 household, cluster (at school and factory), community (sporadic case in the
507 community) and others (work and social contacts). Severe (dotted line) and critical
508 (solid line) patients were labelled with squared shapes. Asterisks indicate patients in
509 or to other cities (For interpretation of the references to color in this figure legend,
510 please refer to the web version of this article.)

511
512 **Fig2 Serum SARS-CoV-2 IgM and IgG antibody levels on admission and in**
513 **convalescence in the 226 individuals infected with SARS-CoV-2 Delta (B.1.167.2).**

514 Dots represent IgM/IgG level in children aged <12 years (group1) and those aged ≥
515 12years (group2). Box plots indicate the median and interquartile range (IQR) and the
516 whiskers represent the maximum and minimum values. The results showed lower
517 COVID antibody IgM and IgG level on admission, and IgG level in convalescence
518 [0.13(0.00,0.09) vs. 0.12(0.03,0.41), $p < 0.05$; 0.02(0.00,0.14) vs. 1.94(0.54,6.40), p
519 < 0.05 ; 5.46(2.41,9.26) vs. 73.63(54.63,86.55), $p < 0.05$, respectively], but higher
520 antibody IgM level in convalescence [1.05(0.51,2.31) vs. 0.51(0.20,1.69), $p=0.016$].

521
522
523
524
525
526
527
528
529
530
531
532
533

534

535

536 **Table 1: Baseline information of 226 individuals infected with SARS-CoV-2 Delta**
537 **B.1.167.2**

	All patients (n = 226)	<12 (n=77)	>=12 (n=149)
Age	32[9,46]	9[6,9]	39[32,50]
Gender			
Male	94	44 (57.14%)	50 (33.56%)
Female	132	33 (42.86%)	99 (66.44%)
Vaccinated (%)	141	0 (0.00%)	141 (94.63%)
One-dose vaccination	9	0 (0.00%)	9 (6.04%)
Two-dose vaccination	132	0 (0.00%)	132 (88.59%)
Basic illness	18	0 (0.00%)	18 (12.08%)
Diabetes	11	0 (0.00%)	11 (7.38%)
Hypertension	6	0 (0.00%)	6 (4.03%)
Cardiovascular diseases	0	0 (0.00%)	0 (0.00%)
Chronic liver diseases	0	0 (0.00%)	0 (0.00%)
Respiratory diseases	0	0 (0.00%)	0 (0.00%)
Nervous system diseases	0	0 (0.00%)	0 (0.00%)
Blood system diseases	0	0 (0.00%)	0 (0.00%)
Chronic kidney diseases	1	0 (0.00%)	1 (0.67%)
Metabolic disease	0	0 (0.00%)	0 (0.00%)
Tumor	0	0 (0.00%)	0 (0.00%)

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554 **Table2: Comparative analysis of clinical features of SARS-Cov-2 Delta (B.1.167.2)**

555 **infection between children aged<12y and patients aged≥ 12y**

556

	All patients (n = 226)	<12 (n=77)	≥12 (n=149)	P-value
Clinical features				
Fever n (%)	147	58(75.32%)	89(59.73%)	0.02
Degrees of Fever n (%)				0.05
Low fever n (%)	61	31(40.26%)	30(20.13%)	
Moderate fever n (%)	58	21(27.27%)	37(24.83%)	
High fever n (%)	27	7(9.09%)	20(13.42%)	
Cough n (%)	80	14(18.18%)	66(44.30%)	<0.001
Expectoration n (%)	42	6 (7.79%)	36(24.16%)	0.002
Nasal congestion n (%)	3	0 (0.00%)	3(2.01%)	0.553
Sore throat n (%)	4	0 (0.00%)	4(2.68%)	0.302
Dyspnea n (%)	3	0 (0.00%)	3(2.01%)	0.553
Fatigue n (%)	64	13 (16.88%)	51(34.23%)	0.006
Inappetence n (%)	8	2 (2.60%)	6(4.03%)	0.719
Headache or Sore muscle n (%)	13	3 (3.90%)	10(6.71%)	0.55
Diarrhea n (%)	7	2 (2.60%)	5(3.36%)	1
CT value at diagnosis (ORF1lab)	22.20 [17.27 , 27.26]	21.28 [17.74 ,26.15]	23.21[17.09 , 27.51]	0.38

	21.90	20.68	22.50	
CT value at diagnosis (N)	[15.61 , 26.32]	[15.93 ,25.33]	[15.59 , 26.79]	0.463
Fever onset after diagnosis				
Median (IQR)	1[1,4]	1[1,3]	2[1,4]	0.31
Fever time Median (IQR)	1[0,3]	1[0,2.5]	1[0,3.5]	0.998
Disease severity				0.127
Asymptomatic	5	5(6.49%)	0(0.00%)	—
Mild	83	34 (44.16%)	49(32.89%)	—
Moderate	132	38 (49.35%)	94(63.09%)	—
Severe	4	0(0.00%)	4(2.68%)	—
Critical	2	0(0.00%)	2(1.34%)	—
Laboratory diagnostics				
WBC count(x10 ⁹ /L)average (SD)	6.25(2.01)	5.89(1.90)	6.45(2.04)	0.05
Lymphocyte count (x10 ⁹ /L)	1.46	1.84	1.31	
Median (IQR)	[1.02,2.22]	[1.32,2.71]	[0.94,1.85]	<0.001
CRP<5mg/l	157	71(92.21%)	86(57.72%)	<0.001
IL-6(pg/ml)	7.00	5.28	9.10	
	[3.82 ,13.98]	[3.31,8.13]	[4.37,15.14]	<0.001
APTT (s) Median (IQR)	28.00 [23.98,31.35]	29.7 [26.1,32.4]	27.00 [23.2,30.30]	0.002
D-D (ug/ml)	0.31 [0.18,0.53]	0.30 [0.22,0.47]	0.32 [0.17,0.54]	0.549
AST(U/L),Median (IQR)	22.40 [17.35,29.58]	26.50 [22.22,32.90]	19.80 [16.20,26.6 0]	<0.001
ALT(U/L),Median (IQR)	13.10 [9.70,21.00]	12.50 [9.50,17.00]	14 [9.83,25.10]	0.039
LDH(U/L)	223.10(65.5 3)	263.88(71.70)	202.263(51. 01)	<0.001

IgG level on admission (COI)	0.97 [0.017,4.03]	0.02 [0.00,0.14]	1.94 [0.54,6.40]	<0.001
IgM level on admission (COI)	0.068 [0.01,0.30]	0.13 [0.00,0.09]	0.12 [0.034,0.41]	<0.001
IgG level in convalescence (COI)	60.64 [5.27,82.48]	5.46 [2.41,9.26]	73.63 [54.63,86.55]	<0.001
IgM level in convalescence (COI)	0.76 [0.24,1.82]	1.05 [0.51,2.31]	0.51 [0.20,1.69]	0.016
Treatment and prognosis				
Pneumonia n (%)	135	41(53.25%)	94(63.09%)	0.12
Respiratory failure n (%)	6	0(0.00%)	6(4.03%)	0.302
Intubation rate,n (%)	2	0(0.00%)	2(1.34%)	0.549
TCM treatment,n (%)	214	67(87.01%)	147(98.66%)	<0.001
Antibiotic usage rate, n (%)	15	7(9.09%)	8(5.37%)	0.398
Neutralizing antibody of BRIL,n (%)	42	0(0.00%)	42(28.19%)	<0.001
Convalescent plasma therapy,n (%)	5	0(0.00%)	5(3.36%)	0.169
Hormone therapy,n (%)	2	0(0.00%)	2(1.34%)	0.549
ICU occupancy	5	0(0.00%)	5(3.36%)	0.315
Nucleic acid negativization time(days),Median (IQR)	16[12,22]	18[13,23.5]	16[12,21]	0.13
Death rate,n (%)	0	0(0.00%)	0(0.00%)	1

557 1. Data include average (SD), median (IQR), n (%) or n/N (%). N is the number of
558 patients with available data.2. The category variable is "number of people
559 (proportion)", In numerical variables, the normal variable is "mean (standard
560 deviation)" and the non-normal variable is "median (quartile spacing, quartile
561 spacing)".

562

563 **Table3 The effect factors related to NAN time for the patients with SARS-Cov-2**
564 **Delta (B.1.167.2) infection**

565

	Coefficients	Std. Error	P-value
(Intercept)	17.39952	1.96963	<0.0001***
Fever onset after diagnosis	-0.31900	0.12200	0.00957**
IgG level on admission	-0.03822	0.01846	0.03967*
CT value at diagnosis	-0.09493	0.05040	0.05000*
ORF1lab			
Degrees of Fever			
Low fever	0.83710	0.81097	0.30315
Moderate fever	0.97663	1.08943	0.37103
High fever	2.80145	1.02665	0.00689*
Pneumonia	3.08877	0.82044	0.00022***
Disease severity			
Mild	1.48801	2.10680	0.48078
Moderate	0.19659	2.17822	0.92817
Severe	2.92080	3.29679	0.37665
Critical	15.03535	3.49264	0.00003***
Group2	-4.71411	1.53909	0.00248**

566 *indicates that the P value of the variable is less than 0.05.

567 **indicates that the P value of the variable is less than 0.01.

568 ***indicates that the P value is less than 0.001.

569 In the exploration of NAN time of patients, because most indicators do not obey
570 normal distribution, this article adopts the method of least squares estimation to
571 evaluate 25 possible influencing variables such as fever duration, type, lymphocyte
572 count, etc. Based on the existing data, this paper uses R data analysis software to
573 model the data, and gradually removes the insignificant influencing factors to obtain
574 the above related factors.

575

576 NAN: Nucleic acid negativization

577

578

Generation

Poor prognosis

Transmission

City

a)

b)

c)

d)